[1] |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158.
|
[2] |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 [J]. Lancet, 2020, 396(10258): 1204-1222.
|
[3] |
中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南 [J]. 中华心血管病杂志, 2020, 48(12): 1000-1038.
|
[4] |
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [J]. Circulation, 2019, 140(11): e596-e646.
|
[5] |
Mao Q, Huang JF, Lu X, et al. Heart rate influence on incidence of cardiovascular disease among adults in China [J]. Int J Epidemiol, 2010, 39(6): 1638-1646.
|
[6] |
Zhang D, Wang W, Li F. Association between resting heart rate and coronary artery disease, stroke, sudden death and noncardiovascular diseases: a meta-analysis [J]. CMAJ, 2016, 188(15): E384-E392.
|
[7] |
Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis [J]. CMAJ, 2016, 188(3): E53-E63.
|
[8] |
Jing F Y, Wang X L, Song J L, et al. Association between clustering of cardiovascular risk factors and resting heart rate in Chinese population: a cross-sectional study [J]. J Geriatr Cardiol, 2022, 19(6): 418-427.
|
[9] |
Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese Population: the China-PAR project (Prediction for ASCVD Risk in China) [J]. Circulation, 2016, 134(19): 1430-1440.
|
[10] |
中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南 [J]. 中华预防医学杂志, 2019, 53(1): 13-35.
|
[11] |
Wong GW, Wright JM. Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension [J]. Cochrane Database Syst Rev, 2014, (2): CD007452.
|
[12] |
Wong G W, Laugerotte A, Wright JM. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension [J]. Cochrane Database Syst Rev, 2015, 2015(8): CD007449.
|
[13] |
Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension [J]. Cochrane Database Syst Rev, 2016, 3(3): CD007451.
|
[14] |
Chen JM, Heran BS, Perez MI, et al. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension [J]. Cochrane Database Syst Rev, 2010, (1): CD007185.
|
[15] |
Lee DH, de Rezende L, Hu FB, et al. Resting heart rate and risk of type 2 diabetes: a prospective cohort study and meta-analysis[J]. Diabetes Metab Res Rev, 2019, 35(2):e3095.
|
[16] |
孙浩航, 牛振民, 赵阳, 等. 静息心率与高血压发病风险的关系及性别、年龄对其的修饰效应 [J]. 中华心血管病杂志, 2020, 48(1): 54-60.
|
[17] |
Colangelo LA, Yano Y, Jacobs DR JR, et al. Association of resting heart rate with blood pressure and incident hypertension over 30 years in black and white adults: the CARDIA Study [J]. Hypertension, 2020, 76(3): 692-698.
|
[18] |
Bønaa K H, Arnesen E. Association between heart rate and atherogenic blood lipid fractions in a population. The Tromsø Study [J]. Circulation, 1992, 86(2): 394-405.
|
[19] |
许金鹏, 蒋钟吉, 廖碧红. 静息心率与心血管疾病关系研究进展 [J]. 内科, 2022, 17(2): 180-183.
|
[20] |
Custodis F, Schirmer S H, Baumhäkel M, et al. Vascular pathophysiology in response to increased heart rate [J]. J Am Coll Cardiol, 2010, 56(24): 1973-1983.
|
[21] |
St Pierre SR, Peirlinck M, Kuhl E. Sex matters: a comprehensive comparison of female and male hearts [J]. Front Physiol, 2022, 13: 831179.
|
[22] |
Heiss HW, Barmeyer J, Wink K, et al. Studies on the regulation of myocardial blood flow in man. I.: Training effects on blood flow and metabolism of the healthy heart at rest and during standardized heavy exercise [J]. Basic Res Cardiol, 1976, 71(6): 658-675.
|